Shengfang Jin, ENSEM president and CSO

With an eye to 'non-ob­vi­ous bind­ing sites,' CBC Group launch­es pre­ci­sion med­i­cine play with $67M and ex-Ed­i­tas ex­ec at the helm

Over the past year, CBC Group has been qui­et­ly in­cu­bat­ing a biotech to take ad­van­tage of the AI rush and make some new ther­a­pies against hard-to-drug on­col­o­gy tar­gets. And it’s now en­ticed a tech in­vestor to pick up the tab on the Se­ries A.

EN­SEM Ther­a­peu­tics is launch­ing with $67 mil­lion from GGV Cap­i­tal — which has backed com­pa­nies like Airbnb, Al­iba­ba and Slack — and Pavil­ion Cap­i­tal, Cen­o­va Cap­i­tal, Mit­sui & Co. Glob­al In­vest­ment and CBC Group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.